SAN FRANCISCO, June 2, 2016 /PRNewswire/ -- Nektar
Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer,
Howard W. Robin, is scheduled to
present at the upcoming Jefferies 2016 Global Healthcare Conference
in New York City on Wednesday, June 8, 2016 at 11:30 a.m. Eastern time.
The presentation will be accessible via a Webcast through a link
posted on the Investor Relations, Events Calendar section of the
Nektar website: http://www.nektar.com. This Webcast will be
available for replay until July 8,
2016.
About Nektar
Nektar Therapeutics has a robust
R&D pipeline and portfolio of approved partnered medicines in
oncology, pain, immunology and other therapeutic areas. In
oncology, Nektar is developing NKTR-214, an
immuno-stimulatory CD122-biased agonist, that is in Phase 1/2
clinical development for patients with solid tumors. ONZEALD™
(etirinotecan pegol), a long-acting topoisomerase I inhibitor,
is being developed for patients with advanced breast cancer
and brain metastases and is partnered with Daiichi Sankyo in
Europe. In the area of pain, Nektar has an exclusive
worldwide license agreement with AstraZeneca for MOVANTIK™
(naloxegol), the first FDA-approved once-daily oral
peripherally-acting mu-opioid receptor antagonist (PAMORA)
medication for the treatment of opioid-induced constipation (OIC),
in adult patients with chronic, non-cancer pain. The product is
also approved in the European Union as MOVENTIG®
(naloxegol) and is indicated for adult patients with OIC who have
had an inadequate response to laxatives. NKTR-181, a wholly owned
mu-opioid analgesic molecule for chronic pain conditions, is in
Phase 3 development. In hemophilia, Nektar has a
collaboration agreement with Baxalta for ADYNOVATE™ [Antihemophilic
Factor (Recombinant)], a longer-acting PEGylated Factor VIII
therapeutic approved in the U.S. and Japan for
patients over 12 with hemophilia A. In anti-infectives, the company
has two collaborations with Bayer Healthcare, Cipro Inhale in
Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin Inhale
in Phase 3 for patients with Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in
the U.S. or Europe through partnerships with
leading biopharmaceutical companies, including AstraZeneca's
MOVANTIK™, Baxalta's ADYNOVATE™, UCB's Cimzia® for Crohn's disease
and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and
Amgen's Neulasta® for neutropenia.
Nektar is headquartered in San Francisco, California, with additional operations
in Huntsville, Alabama and Hyderabad, India. Further information about the company
and its drug development programs and capabilities may be found
online at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies.
ADYNOVATE™ is a trademark of Baxalta Inc.
ONZEALD™ is a trademark of Nektar Therapeutics.
Contact:
Investors
Jennifer Ruddock of Nektar
Therapeutics
415-482-5585
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-jefferies-2016-global-healthcare-conference-in-new-york-city-300279175.html
SOURCE Nektar Therapeutics